Beren Therapeutics

Coming – September 17

A Powerful Approach to Childhood Dementia

Date and Time

September 17

–

4:00 PM ET / 1:00 PM PT

Details will be shared with confirmed attendees

About this Event

Beren Therapeutics is a late-stage biotechnology company developing a new class of medicines designed to restore intracellular cholesterol trafficking, a biological process increasingly implicated across numerous neurodegenerative diseases, including Alzheimer’s disease.

The company’s first clinical validation comes from Niemann-Pick disease type C (NPC), a devastating, rare childhood dementia caused by defective intracellular cholesterol trafficking. Beren’s lead medicine, adrabetadex, is under FDA Priority Review with a November 17, 2026 decision date. In the primary analysis submitted to the FDA, 84% of treated patients were alive five years after treatment initiation compared with 42% of matched untreated patients. Beren forecasts approximately $1.2 billion in annual peak global sales for adrabetadex in NPC alone.

Building on this foundation, Beren is developing multiple additional medicines targeting cholesterol trafficking in Alzheimer’s disease and other neurodegenerative disorders. is led by an ambitious founder-CEO and the management team has contributed to more than 46 FDA-approved medicines.

Join our executive briefing with Beren co-founder and CEO, Jason Camm, to hear how the company has fully funded the U.S. commercialization of adrabetadex and plans to accelerate additional disease programs, expand its portfolio, and pursue international growth.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.